Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 541

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 541
---
 http://www.sec.gov. If you would like additional copies of this proxy statement/prospectus or if you have questions about the Business Combination or the proposals to be presented at the BLAC’s Stockholders’ Meeting, you should contact us at the following address or by email: Bellevue Life Sciences Acquisition Corp.
10900 NE 4 thStreet, Suite 2300
Bellevue, WA 98004
Attn: Jun Chul Whang
Email: group@bellevuecm.com
jcwhang@bellevuecm.com You may also obtain these documents by requesting them in writing or by telephone from our proxy solicitation agent at the following address and telephone number: Advantage Proxy, Inc.
P.O. Box 10904
Yakima, WA 98909
Attn: Karen Smith
Toll Free Telephone: (877) 870 -8565
Main Telephone: (206) 870 -8565
E -mail: ksmith@advantageproxy.com If you are a stockholder of BLAC and would like to request documents, please do so by no later than five business days before the BLAC Stockholders’ Meeting in order to receive them before such special meeting.If you request any documents from us, we will mail them to you by first class mail, or another equally prompt means. All information contained in this proxy statement/prospectus relating to BLAC has been supplied by BLAC, and all such information relating to OSR Holdings has been supplied by OSR Holdings. Information provided by either BLAC or OSR Holdings does not constitute any representation, estimate or projection of any other party. This document is a proxy statement of BLAC for the BLAC Stockholders’ Meeting. We have not authorized anyone to give any information or make any representation about the Business Combination, us or OSR Holdings that is different from, or in addition to, that contained in this proxy statement/prospectus. Therefore, if anyone does give you information of this sort, you should not rely on it. The information contained in this proxy statement/prospectus speaks only as of the date of this proxy statement/prospectus unless the information specifically indicates that another date applies. 345

INDEX TO FINANCIAL STATEMENTS

| Bellevue Life Sciences Acquisition Corp. Unaudited Condensed Financial Statements                                                    
 Condensed Balance Sheets as of September 30, 2024 (unaudited) and December 31, 2023                                                  
 Condensed Statements of Operations (un